Cortical Lewy body disease and Parkinson's disease dementia

Current Opinion in Neurology

Volumn 19, Issue 6, 2006, Pages 572-579

  Burn, David J ^a  

^a NEWCASTLE GENERAL HOSPITAL   (United Kingdom)

Author keywords

Dementia; Dementia with Lewy bodies; Parkinson's disease

Indexed keywords

ALPHA SYNUCLEIN; CHOLINESTERASE INHIBITOR; DONEPEZIL; LEVODOPA; MEMANTINE; NEUROLEPTIC AGENT;

ALZHEIMER DISEASE; ANXIETY; APATHY; BALANCE DISORDER; BRAIN ATROPHY; BRAIN RADIOGRAPHY; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DIFFUSE LEWY BODY DISEASE; DIFFUSION TENSOR IMAGING; DISEASE EXACERBATION; ECHOGRAPHY; ELECTROOCULOGRAPHY; EPIDEMIOLOGICAL DATA; GAIT DISORDER; HUMAN; INCIDENCE; MENTAL DISEASE; MINI MENTAL STATE EXAMINATION; NEUROFIBRILLARY TANGLE; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PREPULSE INHIBITION; PROTEIN EXPRESSION; REVIEW; RISK FACTOR; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SLEEP DISORDER; TEMPORAL LOBE; VISUAL HALLUCINATION;

ALPHA-SYNUCLEIN; CEREBRAL CORTEX; CHOLINESTERASE INHIBITORS; DIAGNOSIS, DIFFERENTIAL; DIAGNOSTIC IMAGING; DOPAMINE AGENTS; HUMANS; LEWY BODY DISEASE; PARKINSON DISEASE; SENILE PLAQUES;

EID: 33751031873     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.wco.0000247607.34697.a2     Document Type: Review

References (53)

1. Aarsland D, Ballard CG, Halliday G. Are Parkinson's disease with dementia and dementia with Lewy bodies the same entity? J Geriatr Psychiatry Neurol 2004; 17:137-145.
2. Zaccai J, McCracken C, Brayne C. A systematic review of prevalence and incidence studies of dementia with Lewy bodies. Age Ageing 2005; 34:561-566. A thorough review of available descriptive epidemiological data for DLB.
3. de Lau LML, Schipper CMA, Hofman A, et al. Prognosis of Parkinson disease: risk of dementia and mortality: the Rotterdam study. Arch Neurol 2005; 62:1265-1269. Strengths of this study were that it was not hospital based, nor did it simply rely upon register-based case-finding methods.
4. Aarsland D, Zaccai J, Brayne C. A systematic review of prevalence studies of dementia in Parkinson's disease. Mov Disord 2005; 10:1255-1263. State-of-the-art review for the descriptive epidemiology of dementia associated with Parkinson's disease.
5. Haugarvoll K, Aarsland D, Wentzel-Larsen T, Larsen J. The influence of cerebrovascular risk factors on incident dementia in patients with Parkinson's disease. Acta Neurol Scand 2005; 112:386-390.
6. Huang X, Chen P, Kaufer DI, et al. Apolipoprotein E and dementia in Parkinson disease: a meta-analysis. Arch Neurol 2006; 63:189-193. This thoughtful metaanalysis helps to resolve previous, seemingly disparate, results in this area.
7. Janvin C, Larsen J, Salmon D, et al. Cognitive profiles of individual patients with Parkinson's disease and dementia: comparison with dementia with Lewy bodies and Alzheimer's disease. Mov Disord 2006; 21:337-342.
8. Tiraboschi P, Salmon D, Hansen L, et al. What best differentiates Lewy body from Alzheimer's disease in early-stage dementia? Brain 2006; 129:729-735. Comprehensive study in which first-visit data of 23 pathologically proven DLB and 94 Alzheimer's disease cases were compared to determine which clinical features best predicted a diagnosis of DLB.
9. Mosimann U, Rowan E, Partington C, et al. Characteristics of visual hallucinations in Parkinson disease dementia and dementia with Lewy bodies. Am J Geriatr Psychiatry 2006; 14:153-160. A comparative study of the details of hallucination characteristics and associated neuropsychiatric features in DLB and PDD.
10. Weintraub D, Stern M. Psychiatric complications in Parkinson disease. Am J Geriatr Psychiatry 2005; 13:844-851. An overview of the epidemiology, pathophysiology, clinical presentation, and management of the most common psychiatric complications in Parkinson's disease.
11. Allan L, Ballard C, Burn D, Kenny R. Prevalence and severity of gait disorders in Alzheimer's and non-Alzheimer's dementias. J Am Geriatr Soc 2005; 53:1681-1687. A systematic characterisation of gait and balance disturbance in vascular and degenerative dementias and the potential diagnostic value of early gait disorder.
12. Burn D, Rowan E, Allan L, et al. Motor subtype and cognitive decline in Parkinson's disease, Parkinson's disease with dementia, and dementia with Lewy bodies. J Neurol Neurosurg Psychiatry 2006; 77:585-589. A longitudinal study addressing the hypothesis that a postural instability-gait difficulty motor phenotype is associated with incident dementia in Parkinson's disease.
13. Alves G, Larsen JP, Emre M, et al. Changes in motor subtype and risk for incident dementia in Parkinson's disease. Mov Disord on line 2006; 24 April [Epub ahead of print].
14. Sakakibara R, Ito T, Uchiyama T, et al. Lower urinary tract function in dementia of Lewy body type. J Neurol Neurosurg Psychiatry 2005; 76:729-732.
15. Olichney JM, Murphy C, Hofstetter CR, et al. Anosmia is very common in the Lewy body variant of Alzheimer's disease. J Neurol Neurosurg Psychiatry 2005; 76:1342-1347. Testing olfactory function is back in fashion in the synucleinopathies! Anosmia is very common in DLB.
16. McKeith I, Dickson D, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005; 65:1863-1872. This description of the revised diagnostic criteria is essential reading for anyone dealing with DLB or PDD. It also pulls together findings from several recent studies, including sleep disorders and SPECT imaging and puts them in a useful diagnostic context.
17. Miyasaki J, Shannon K, Voon V, et al. Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006; 66:996-1002. Although somewhat 'rigid' in its approach and with conclusions that some might dispute, this is, nevertheless, a worthy and systematic review of the available evidence in this area.
18. Tam C, Burton E, McKeith I, et al. Temporal lobe atrophy on MRI in Parkinson disease with dementia: a comparison with Alzheimer disease and dementia with Lewy bodies. Neurology 2005; 64:861-865.
19. Summerfield C, Junque C, Tolosa E, et al. Structural brain changes in Parkinson disease with dementia: a voxel-based morphometry study. Arch Neurol 2005; 62:281-285. A voxel-based morphometric analysis of MRI scans contributing significantly to the in-vivo identification of cerebral regions predominantly involved in PDD.
20. Hanyu H, Shimizu S, Tanaka Y, et al. Differences in magnetization transfer ratios of the hippocampus between dementia with Lewy bodies and Alzheimer's disease. Neurosci Lett 2005; 380:166-169.
21. Bozzali M, Falini A, Cercignani M, et al. Brain tissue damage in dementia with Lewy bodies: an in vivo diffusion tensor MRI study. Brain 2005; 128:1595-1604.
22. Walter U, Dressler D, Wolters A, et al. Sonographic discrimination of dementia with Lewy bodies and Parkinson's disease with dementia. J Neurol 2006; 253:448-454. The first published study to use transcranial sonography in an attempt to discriminate between patients with DLB and PDD.
23. Matsui H, Udaka F, Miyoshi T, et al. N-isopropyl-p-123I iodoamphetamine single photon emission computed tomography study of Parkinson's disease with dementia. Intern Med 2005; 44:1046-1050.
24. Shimizu S, Hanyu H, Kanetaka H, et al. Differentiation of dementia with Lewy bodies from Alzheimer's disease using brain SPECT. Dement Geriatr Cogn Disord 2005; 20:25-30. SPECT data from 20 patients with DLB and 75 patients with Alzheimer's disease were analyzed and receiver operating characteristic analysis used to derive sensitivity and specificity of medial occipital lobe regional cerebral blood flow in discriminating DLB from Alzheimer's disease.
25. Firbank M, Burn D, McKeith I, O'Brien J. Longitudinal study of cerebral blood flow SPECT in Parkinson's disease with dementia, and dementia with Lewy bodies. Int J Geriatr Psychiatry 2005; 20:776-782.
26. Hilker R, Thomas AV, Klein JC, et al. Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways. Neurology 2005; 65:1716-1722. An interesting dual tracer approach examining covariance between cholinergic and dopaminergic systems in PDD.
27. Bohnen NI, Kaufer DI, Hendrickson R, et al. Cognitive correlates of cortical cholinergic denervation in Parkinson's disease and parkinsonian dementia. J Neurol 2006; 253:242-247. Extends this group's previous finding of significant cortical cholinergic dysfunction in PDD and Parkinson's disease by correlating PET findings with neuropsychological test data.
28. Colloby S, Williams E, Burn D, et al. Progression of dopaminergic degeneration in dementia with Lewy bodies and Parkinson's disease with and without dementia assessed using 123I-FP-CIT SPECT. Eur J Nucl Med Mol Imaging 2005; 32:1176-1185. First study to investigate the rate of progression of nigrostriatal dopaminergic loss in DLB, Parkinson's disease and PDD using serial 123I-FP-CIT SPECT imaging.
29. Suzuki M, Kurita A, Hashimoto M, et al. Impaired myocardial 123I-metaiodobenzylguanidine uptake in Lewy body disease: comparison between dementia with Lewy bodies and Parkinson's disease. J Neurol Sci 2006; 240:15-19. A comparison of cardiac sympathetic function between DLB and Parkinson's disease in early disease stage, measured with 123I-MIBG scintigraphy.
30. Hanyu H, Shimizu S, Hirao K, et al. Comparative value of brain perfusion SPECT and [(123)I]MIBG myocardial scintigraphy in distinguishing between dementia with Lewy bodies and Alzheimer's disease. Eur J Nucl Med Mol Imaging 2006; 33:248-253.
31. Mosimann U, Muri R, Burn D, et al. Saccadic eye movement changes in Parkinson's disease dementia and dementia with Lewy bodies. Brain 2005; 128:1267-1276. A comparative study of impairments in reflexive and complex saccades between subjects with Parkinson's disease, PDD, DLB and Alzheimer's disease.
32. Perriol M, Dujardin K, Derambure P, et al. Disturbance of sensory filtering in dementia with Lewy bodies: comparison with Parkinson's disease dementia and Alzheimer's disease. J Neurol Neurosurg Psychiatry 2005; 76:106-108.
33. Devos D, Tir M, Maurage C, et al. ERG and anatomical abnormalities suggesting retinopathy in dementia with Lewy bodies. Neurology 2005; 65:1107-1110.
34. Bibl M, Mollenhauer B, Esselmann H, et al. CSF amyloid-(beta)-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia. Brain 2006; 129:1177-1187.
35. Mollenhauer B, Bibl M, Trenkwalder C, et al. Follow-up investigations in cerebrospinal fluid of patients with dementia with Lewy bodies and Alzheimer's disease. J Neural Transm 2005; 112:933-948.
36. •] complement each other in analysing the cognitive features of patients with postmortem confirmed DLB and Alzheimer's disease, although differ in their conclusions regarding rate of cognitive decline.
37. •] complement each other in analysing the cognitive features of patients with postmortem confirmed DLB and Alzheimer's disease, although differ in their conclusions regarding rate of cognitive decline.
38. Braak H, Rub U, Jansen SE, et al. Cognitive status correlates with neuropathologic stage in Parkinson disease. Neurology 2005; 64:1404-1410. The hugely influential Braak staging system for Parkinson's disease correlated with antemortem cognitive function.
39. Aarsland D, Perry R, Brown A, et al. Neuropathology of dementia in Parkinson's disease: a prospective, community-based study. Ann Neurol 2005; 58:773-776. Although the case numbers are quite low, the strengths of this study, alluded to in the title, are its prospective and community-based nature, making it unique.
40. Parkkinen L, Kauppinen T, Pirttila T, et al. Alpha-synuclein pathology does not predict extrapyramidal symptoms or dementia. Ann Neurol 2005; 57:82-91. Retrospective clinical assessment showing that only 32 (30%) of 106 α-synuclein-positive cases at postmortem were diagnosed with a neurodegenerative disorder.
41. Pletnikova O, West N, Lee M, et al. Abeta deposition is associated with enhanced cortical alpha-synuclein lesions in Lewy body diseases. Neurobiol Aging 2005; 26:1183-1192. In Parkinson's disease and DLB, Aβ deposits in the cerebral cortex are associated with extensive a-synuclein lesions and higher levels of insoluble α-synuclein, supporting the notion of 'protein-protein synergy'.
42. Hofer A, Berg D, Asmus F, et al. The role of alpha-synuclein gene multiplications in early-onset Parkinson's disease and dementia with Lewy bodies. J Neural Transm 2005; 112:1249-1254.
43. Cantuti-Castelvetri I, Klucken J, Ingelsson M, et al. Alpha-synuclein and chaperones in dementia with Lewy bodies. J Neuropathol Exp Neurol 2005; 64:1058-1066.
44. Maidment I, Fox C, Boustani M. Cholinesterase inhibitors for Parkinson's disease dementia. Cochrane Database Syst Rev 2006; CD004747. Although limited effectively to the EXPRESS study data, this review makes some useful observations of potential shortcomings and suggestions for future study design.
45. Poewe W. Treatment of dementia with Lewy bodies and Parkinson's disease dementia. Mov Disord 2005; 20 (Suppl 12):S77-S82. An excellent, comprehensive and pragmatic review of the management of PDD and DLB.
46. Poewe W, Wolters E, Emre M, et al. Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: an active treatment extension study. Mov Disord 2006; 21:456-461. Notable for the cohort size (an extension of the EXPRESS study, previously published in the New England Journal of Medicine) and the rigorous design.
47. Ravina B, Putt M, Siderowf A, et al. Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study. J Neurol Neurosurg Psychiatry 2005; 76:934-939. Although relatively small, this was a well conducted study with increased power through its cross-over design.
48. Thomas A, Burn D, Rowan E, et al. A comparison of the efficacy of donepezil in Parkinson's disease with dementia and dementia with Lewy bodies. Int J Geriatr Psychiatry 2005; 20:938-944.
49. Aarsland D, Perry R, Larsen J, et al. Neuroleptic sensitivity in Parkinson's disease and parkinsonian dementias. J Clin Psychiatry 2005; 66:633-637.
50. Ballard C, Perry R, McKeith I, Perry E. Neuroleptics are associated with more severe tangle pathology in dementia with Lewy bodies. Int J Geriatr Psychiatry 2005; 20:872-875.
51. Sabbagh MN, Hake AM, Ahmed S, Farlow MR. The use of memantine in dementia with Lewy bodies. J Alzheimers Dis 2005; 7:285-289. Open and observational with small patient numbers, this study is, nevertheless, notable as it is the first report of the use of memantine in DLB.
52. Ridha B, Josephs K, Rossor M. Delusions and hallucinations in dementia with Lewy bodies: worsening with memantine. Neurology 2005; 65:481-482.
53. Molloy S, McKeith I, O'Brien J, Burn D. The role of levodopa in the management of dementia with Lewy bodies. J Neurol Neurosurg Psychiatry 2005; 76:1200-1203. A comparative study in Parkinson's disease, PDD and DLB of the motor response to levodopa, administered by acute challenge and also over 3 months.